(Q36338031)

13 August 2017

1 reference

title

Combination therapy with DNA methyltransferase inhibitors in hematologic malignancies (English)

1 reference

13 August 2017

Steven D Gore

1

1 reference

13 August 2017

language of work or name

1 reference

1 December 2005

1 reference

Nature Clinical Practice Oncology

13 August 2017

published in

1 reference

13 August 2017

volume

2 Suppl 1

1 reference

13 August 2017

page(s)

S30-5

1 reference

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0346

7 January 2021

Myelodysplastic syndromes.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0346

7 January 2021

Induction of differentiation and apoptosis- a possible strategy in the treatment of adult acute myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0346

7 January 2021

New agents in acute myeloid leukemia and other myeloid disorders

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0346

7 January 2021

Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0346

7 January 2021

Gene silencing in cancer in association with promoter hypermethylation

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0346

7 January 2021

Role of the ras-MAPK signaling pathway in the DNA methyltransferase response to DNA hypomethylation

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0346

7 January 2021

Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0346

7 January 2021

Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-beta-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumab

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0346

7 January 2021

Efficacy of lenalidomide in myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0346

7 January 2021

Identifiers

DOI

10.1038/NCPONC0346

1 reference

13 August 2017

1 reference